L. B. Bohle’s Technology Center Merges All Steps of Continuous Production
With the inauguration of the Technology Center, the engineers, scientists, pharmacists, and IT developers for the first time closed the loop control circuit of a modular system along the entire process including production, sensor technology and controlling.
L.B. Bohle Maschinen + Verfahren GmbH has inaugurated its Technology Center at the Bohle headquarters in Ennigerloh, creating a platform for new processes and knowledge transfer. With the inauguration of the Technology Center, the engineers, scientists, pharmacists, and IT developers for the first time closed the loop control circuit of a modular system along the entire process including production, sensor technology and controlling.
"Series production is set to start as soon as we have received FDA clearance. There is no need to develop, install, and validate a new production line," explained Hubertus Rehbaum, manager scientific operation at Bohle, in a press statement.
According to the company, essential elements of success for this project include having good machines at all process steps that are optimally linked, both physically and technically, in terms of data. Secondly, the machines must be equipped with sensor and measurement technology and all the data must be integrated on a common platform via standardized interfaces.
The software integration, in turn, forms the basis of permanent monitoring, controlling, and documentation of the continuous production process. Advanced spectroscopy technologies, such as NIR and Raman, enable precise measurement and analysis during the individual production steps. Companies such as Kaiser Optical Systems, Sentronic, and Kraemer Elektronik, were involved in the project.
L.B. Bohle stated that the major challenge arose from directly processing this generated data and making it available for use. Together with the IT partners and university scientists, models had to be developed for simulating various processes as well as for defining and automatically initiating corresponding measures and interventions.
Lorenz Bohle mentioned that the unique feature of the company’s Technology Center, is that “the tablet production can be implemented either without granulation or with dry or wet granulation in one system.”
The modular concept of continuous production offers time savings because it does not require any time-consuming analyses of the product samples between the process steps. Moreover, producers benefit from greater flexibility because the plant can be quickly converted to different products.
Source: L. B. Bohle
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
